Nuclear proliferation

CACI Wins $1.4 Billion Task Order with the Defense Threat Reduction Agency to Counter and Deter Various Threats

Retrieved on: 
Tuesday, July 20, 2021

CACI International Inc ( NYSE: CACI ) has been awarded the Defense Threat Reduction Agencys (DTRA) Decisive Action Task order, a single-award task order worth approximately $1.4 billion to continue providing DTRA with mission expertise in support of countering and deterring Weapons of Mass Destruction (WMD), and threat networks.

Key Points: 
  • CACI International Inc ( NYSE: CACI ) has been awarded the Defense Threat Reduction Agencys (DTRA) Decisive Action Task order, a single-award task order worth approximately $1.4 billion to continue providing DTRA with mission expertise in support of countering and deterring Weapons of Mass Destruction (WMD), and threat networks.
  • John Mengucci , CACI President and Chief Executive Officer, said, CACIs understanding of DTRAs critical mission spans more than 14 years.
  • This task order continues and expands CACIs previous work as part of the Joint Improvised-Threat Defeat Organizations (JIDO) Focused Support/Decisive Effort (FS/DE) task order .
  • Under this task order, CACI will provide DTRA with a wide range of analytical expertise to drive and enable mission solutions to counter and deter multi-faceted threats.

CNL Talks Nuclear Energy at Arctic Development Expo

Retrieved on: 
Friday, June 18, 2021

To learn more about the Arctic Development Expo, visit www.arcticdevelopmentexpo.com/ .

Key Points: 
  • To learn more about the Arctic Development Expo, visit www.arcticdevelopmentexpo.com/ .
  • Canadian Nuclear Laboratories is a world leader in nuclear science and technology offering unique capabilities and solutions across a wide range of industries.
  • Actively involved with industry-driven research and development in nuclear, transportation, clean technology, energy, defence, security and life sciences, we provide solutions to keep these sectors competitive internationally.
  • For more information on the complete range of Canadian Nuclear Laboratories services, please visit www.cnl.ca or contact [email protected] .

The Good ISIS - NEW INFO & ANALYSIS - Iran Nuclear Program & IAEA Report on Iran, Upcoming IAEA Board of Governors Meeting

Retrieved on: 
Wednesday, June 2, 2021

What: David Albright answers questions on Iran's nuclear program, the latest reports by the International Atomic Energy Organization (IAEA), and his new groundbreaking book: Iran's Perilous Pursuit of Nuclear Weapons .

Key Points: 
  • What: David Albright answers questions on Iran's nuclear program, the latest reports by the International Atomic Energy Organization (IAEA), and his new groundbreaking book: Iran's Perilous Pursuit of Nuclear Weapons .
  • Albright answers Q's on Iran nuke program, new IAEA report & his new book: Iran's Perilous Pursuit of Nuclear Weapons.
  • Albright will discuss and be available to answer questions on Iran's past and current nuclear weapons capabilities and recent IAEA reports on Iran's nuclear advances, safeguards issues, and continued stonewalling of inspectors.
  • 6) Today, Iran does not appear to have a program focused on the actual building of nuclear weapons.

NTI-Tss Plus® and NTI OmniSplint® Now Available From Glidewell

Retrieved on: 
Tuesday, June 1, 2021

Now, the largest dental lab in the country can also supply dentists with two devices proven effective at relieving their patients' tension headaches and migraines: the NTI-tss Plus and the NTI OmniSplint.

Key Points: 
  • Now, the largest dental lab in the country can also supply dentists with two devices proven effective at relieving their patients' tension headaches and migraines: the NTI-tss Plus and the NTI OmniSplint.
  • The OmniSplint can be prescribed from Glidewell for $140, and both the NTI-tss Plus and the OmniSplint are covered by a 6-month warranty.
  • To learn more about the NTI-tss Plus and the NTI OmniSplint, visit glidewell.com or call 866-335-0744.
  • NTI-tss Plus is a registered trademark of Boyd Research, Inc. NTI OmniSplint is a registered trademark of James Boyd.

CNL’s Gina Strati Joins Office of the Chief Science Advisor of Canada

Retrieved on: 
Tuesday, April 20, 2021

b'CHALK RIVER, Ontario, April 20, 2021 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada\xe2\x80\x99s premier nuclear science and technology organization, is pleased to announce that the Head of its Advanced Reactors Directorate, Dr. Gina Strati, has joined the Office of the Chief Science Advisor of Canada through an executive interchange.

Key Points: 
  • b'CHALK RIVER, Ontario, April 20, 2021 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada\xe2\x80\x99s premier nuclear science and technology organization, is pleased to announce that the Head of its Advanced Reactors Directorate, Dr. Gina Strati, has joined the Office of the Chief Science Advisor of Canada through an executive interchange.
  • A passionate advocate of science and technology, and a leading CNL scientist with expertise in nuclear research, chemistry and material sciences, Dr. Strati will serve as a senior advisor within the distinguished organization.\nIn her new role, Dr. Strati will support the Office in the area of emerging technologies.
  • In pursuit of these goals, our senior leaders regularly take assignments with other industries, institutions and government bodies.
  • For more information on the Office of the Chief Science Advisor of Canada, please visit https://www.ic.gc.ca/ .\nCanadian Nuclear Laboratories is a world leader in nuclear science and technology offering unique capabilities and solutions across a wide range of industries.

Lightbridge Awarded Second US Department of Energy GAIN Voucher for Advanced Nuclear Technology Innovation

Retrieved on: 
Thursday, March 25, 2021

RESTON, Va., March 25, 2021 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced that it was awarded its second voucher from the U.S. Department of Energys (DOE) Gateway for Accelerated Innovation in Nuclear (GAIN) program to support development of Lightbridge Fuel.

Key Points: 
  • RESTON, Va., March 25, 2021 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, today announced that it was awarded its second voucher from the U.S. Department of Energys (DOE) Gateway for Accelerated Innovation in Nuclear (GAIN) program to support development of Lightbridge Fuel.
  • Seth Grae, President & Chief Executive Officer of Lightbridge Corporation, commented: We are proud to have been awarded a second GAIN voucher from the DOE, which further validates our advanced nuclear technology and our fuel development efforts.
  • Lightbridge (NASDAQ: LTBR) is an advanced nuclear fuel technology development company based in Reston, Virginia, United States.
  • The Company is developing Lightbridge Fuel, a proprietary next-generation nuclear fuel technology for current and future reactors, which significantly enhances the economics, safety, and proliferation resistance of nuclear power.

Lightbridge Applauds the American Nuclear Society’s Report: The U.S. Nuclear R&D Imperative

Retrieved on: 
Wednesday, February 17, 2021

RESTON, Va., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, congratulates the American Nuclear Society (ANS) on todays release of The U.S. Nuclear R&D Imperative, a report from the ANS Task Force on Public Investment in Nuclear Research and Development.

Key Points: 
  • RESTON, Va., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Lightbridge Corporation (Nasdaq: LTBR), an advanced nuclear fuel technology company, congratulates the American Nuclear Society (ANS) on todays release of The U.S. Nuclear R&D Imperative, a report from the ANS Task Force on Public Investment in Nuclear Research and Development.
  • Lightbridge President and CEO Seth Grae serves on this task force and was a contributor to this report.
  • The Company is developing Lightbridge Fuel, a proprietary next-generation nuclear fuel technology for current and future reactors, which significantly enhances the economics, safety, and proliferation resistance of nuclear power.
  • Four large electric utilities that generate about half of Americas nuclear power advise Lightbridge on fuel development and deployment.

Report Urges U.S. and Allies to Recommit to Prevent Nuclear Proliferation

Retrieved on: 
Wednesday, February 10, 2021

The report offers specific recommendations and a framework to ensure Americas allies will continue to feel secure without requiring their own nuclear weapons.

Key Points: 
  • The report offers specific recommendations and a framework to ensure Americas allies will continue to feel secure without requiring their own nuclear weapons.
  • Recommitting to Americas allies requires recommitting to nuclear deterrence, said Hagel, former U.S. Secretary of Defense.
  • The report, Preventing Nuclear Proliferation and Reassuring Americas Allies , is the product of the Task Force on U.S.
  • France and Britain should deepen their nuclear cooperation and extend their deterrents to European allies.

Advanced Clinical Joins Decentralized Trials & Research Alliance (DTRA) to Democratize and Accelerate Clinical Trials

Retrieved on: 
Friday, February 5, 2021

Advanced Clinical joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.

Key Points: 
  • Advanced Clinical joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.
  • The Decentralized Trials & Research Alliance ( DTRA ), which launched December 10th, 2020, will unite industry stakeholders, including healthcare companies, regulators, patient groups and research organizations with a singular mission to make clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research.
  • We are extremely gratified to welcome Advanced Clinical to the Decentralized Trials & Research Alliance," said Amir Kalali, MD, founder of several collaborative life science communities, and co-convener of DTRA.
  • The Decentralized Trials & Research Alliance ( DTRA ) was convened to enable collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research.

New START extension: Declaration by the High Representative on behalf of the European Union

Retrieved on: 
Thursday, February 4, 2021

The EU welcomes the agreement reached between the United States and the Russian Federation to extend the New START Treaty for an additional five years.

Key Points: 
  • The EU welcomes the agreement reached between the United States and the Russian Federation to extend the New START Treaty for an additional five years.
  • The EU attaches the highest importance to the New START Treaty and regards it as a crucial contribution to international and European security.
  • By increasing predictability and mutual confidence amongst the two largest nuclear weapon States, this Treaty limits strategic competition and increases strategic stability.
  • The EU stresses the need to preserve and further advance general arms control, disarmament, and non-proliferation processes.